Medytox Inc. 4
4 · Evolus, Inc. · Filed Feb 6, 2023
Insider Transaction Report
Form 4
Evolus, Inc.EOLS
Medytox Inc.
10% Owner
Transactions
- Purchase
Common Stock, $0.00001 par value per share
2021-08-13$11.11/sh+14,043$156,064→ 7,296,543 total(indirect: See Footnote) - Sale
Common Stock, $0.00001 par value per share
2023-01-20$11.04/sh−37,043$408,955→ 7,259,500 total(indirect: See Footnote) - Purchase
Common Stock, $0.00001 par value per share
2021-08-12$10.99/sh+23,000$252,775→ 7,282,500 total(indirect: See Footnote)
Footnotes (4)
- [F1]Inadvertently filed late due to an administrative error.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.88 to $11.10, inclusive. The reporting person undertakes to provide to Evolus, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes 1 to 2.
- [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.91 to $11.26, inclusive.
- [F4]The Issuer shares were previously held of record by Medytox Korea Co., Ltd. ("Medytox Korea"). Medytox, Inc. owns 100% of Medytox Korea. Accordingly, Medytox, Inc. may be deemed to beneficially own indirectly the shares by reason of Medytox Korea's direct beneficial ownership.